The effectiveness of the use of anti-dysbiotic hepatoprotector in the complex treatment of patients with periodontal inflammatory diseases on the background of chronic non-calculous cholecystitis

Abstract

Summary. Inflammatory periodontal diseases continue to be one of the pressing problems of modern dentistry [1]. It is known that there is a close relationship between general-somatic pathology and diseases of the oral cavity [2].

The aim of the study – to learn the effectiveness of the use of anti-dysbiotic hepatoprotector in the complex treatment of patients with periodontal inflammatory diseases on the background of chronic non-calculous cholecystitis.

Materials and Methods. The main (group 1) group consisted of 106 people who suffered from inflammatory periodontal disease (IPD) with concomitant chronic non-calculous cholecystitis (CNC). The comparison group included 92 patients with IPD without concomitant pathology (group 2). To compare the research results of the patients with IPD, 30 healthy teethed individuals without periodontal pathology and without somatic diseases (group 3 or the control group) were involved. The state of the hepatobiliary system in patients of the main group was assessed by the doctors of the Gastroenterology Department of Zolochiv District Hospital of Lviv region.

Results and Discussion. The symptomatic HCG and the presence of solid and soft dental deposits were diagnosed in all patients. The Green-Vermillion’s index was the highest in patients from the main group (1.67±0.01); it was probably (p <0.05) higher than that in the comparison group (1.54±0.04), as well as in the control group (0.44±0.07). The PMA index in the subgroup 1A immediately after treatment decreased by 9.7 (p <0.001) times. The index of bleeding in the subgroup 1A decreased by 10.7 (p <0.001) times. The PMA index in the subgroup 1A immediately after treatment decreased by 10.4 (p <0.001) times. The index of bleeding in the subgroup 1A under the influence of the proposed therapy decreased by 6.5 (p <0.001) times.The difference regarding the data before treatment remained lower by 2.2 times and 2.0 (p <0.001) times, however, the difference between the subgroups 1A and 1B in 3 months and 6 months was already 2.1 times in both cases.

Conclusions. It was found that the clinical course of inflammatory periodontal diseases was much more difficult in these patients. The presence of pathology in the hepatobiliary system in patients increases the risk of periodontal disease. Therefore, in order to improve the efficacy of treatment, it is advisable to use this antidysbiotic drug in the complex treatment, and the results obtained in 3 and 6 months after treatment indicate a long-lasting positive effect.